Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 04 Jun 2024
In this context, the second belantamab mafodotin-containing triplet to demonstrate potency.
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
2.
Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions
3.
Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.
4.
When a Groundbreaking Cancer Therapy Causes Cancer.
5.
Study sheds light on challenges for women of color after breast cancer surgery
1.
Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies
2.
What You Need to Know About the Early Warning Signs of Colon Cancer
3.
Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches
4.
Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge